The present invention relates to a stable rapamycin-containing composition for treating skin diseases, a method of producing the same, a method of stabilizing the same, and a method of inhibiting the degradation of rapamycin.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
NOBELPHARMA CO., LTD. (Japon)
Inventeur(s)
Koseki Michio
Asada Ryuta
Shimizu Kenji
Sanada Chihiro
Hamada Izumi
Abrégé
[Problem] To provide a drug effective for the treatment of an intractable lymphatic disease and an intractable vascular disease. [Solution] Provided is a therapeutic agent for an intractable lymphatic disease and an intractable vascular disease, which contains sirolimus as an active ingredient. The administration of the therapeutic agent is started orally or through a tube at a dose determined depending on a parameter associated with the pharmacokinetics of sirolimus in a patient having the disease and the body weight and the age, in months, of the patient.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/14 - VasoprotecteursAntihémorroïdauxMédicaments pour le traitement des varicesStabilisateurs capillaires
G16H 50/00 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing online medical information in the fields of tuberous sclerosis complex-related Facial Angiofibroma conditions; Providing online medical information of medical treatment for tuberous sclerosis complex-related Facial Angiofibroma conditions
A stent having a tubular shape in a self-expanding state, including: a first wire group including a plurality of wires; and a second wire group including a plurality of wires intersecting with the wires of the first wire group at a plurality of locations, wherein the wires of the first wire group and the wires of the second wire group intersect with each other to form a plurality of cells having a substantially rhombic shape in a state of being self-expanding in a tubular shape, and a cross-sectional shape of each of the wires is a rectangular shape thick in a radial direction of the tubular shape.
A61F 2/915 - Stents ayant une forme caractérisée par des éléments filiformesStents ayant une forme caractérisée par une structure de type filet ou de type à mailles caractérisés par une structure de type filet ou de type à mailles fabriquée à partir de feuilles perforées ou de tubes perforés, p. ex. perforés par découpe au laser ou gravés avec des bandes présentant une structure en méandre, des bandes adjacentes étant reliées l’une à l’autre
5.
PATCH FOR ALLEVIATING OR TREATING SYMPTOMS OF NEURODEGENERATIVE DISEASE
It is an object of the present invention to provide a novel patch for alleviating or treating the symptoms of neurodegenerative disease. According to the present invention, provided is a patch for alleviating or treating the symptoms of neurodegenerative disease, comprising a scopolamine salt and/or a hydrate thereof, wherein the application time of the patch per application is within 48 hours.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
To provide a topical formulation that contains rapamycin, has excellent stability, and is effective in treating a skin disease.
To provide a topical formulation that contains rapamycin, has excellent stability, and is effective in treating a skin disease.
A topical formulation including
(a) rapamycin,
(b) at least one selected from the group consisting of ethylene glycol salicylate, diethyl sebacate, and triacetin, and
(c) propylene glycol and/or polyethylene glycol, the topical formulation further including an antioxidant, and the topical formulation further including a solution of an antioxidant in a lipophilic solvent are provided.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
Provided is a granule in which an unpleasant taste of an active ingredient is masked and immediate release of the active ingredient is maintained, and a method for producing the granule. In particular, provided is the granule containing zinc acetate as an active ingredient having an unpleasant taste, and a method for producing the granule.
Provided is a granule in which an unpleasant taste of an active ingredient is masked and immediate release of the active ingredient is maintained, and a method for producing the granule. In particular, provided is the granule containing zinc acetate as an active ingredient having an unpleasant taste, and a method for producing the granule.
A method for producing a granule in which an unpleasant taste of an active ingredient is masked and immediate release of the active ingredient is maintained. The method includes a step (1) of obtaining a core particle containing an active ingredient having an unpleasant taste, a step (2) of coating a surface of the core particle obtained in the step (1) with ethylcellulose to obtain a particle, and a step (3) of subjecting the particle obtained in the step (2) to a heat treatment in a closed state.
36 - Services financiers, assurances et affaires immobilières
Produits et services
Business administration of patient reimbursement programs; business administration of pharmacy reimbursement programs and services; prior authorization facilitation, also known as healthcare cost containment services, namely, providing expedited review, processing and follow-up of prior authorization requests initiated by physicians' offices and pharmacies; pharmacy referral services provided via a global computer network Providing insurance and insurance reimbursement information; financial administration of patient reimbursement programs, namely, copay financial assistance programs; financial administration of pharmacy reimbursement programs and services; providing patient support services, namely, providing insurance information to help patients understand their insurance and plan benefits, providing information on insurance authorization forms, appeals and status, providing information on insurance-approved site-of-care facilities, and providing insurance reimbursement assistance to eligible patients in the nature of reimbursement payment processing in the field of health and pharmaceutical insurance claims; patient support program, namely, providing information about eligibility for financial assistance provided through patient benefits programs; providing consulting in the field of healthcare insurance benefits; healthcare insurance services, namely, benefit verification services
36 - Services financiers, assurances et affaires immobilières
Produits et services
Business administration of patient reimbursement programs; business administration of pharmacy reimbursement programs and services; prior authorization facilitation, also known as healthcare cost containment services, namely, providing expedited review, processing and follow-up of prior authorization requests initiated by physicians' offices and pharmacies; pharmacy referral services provided via a global computer network Providing insurance and insurance reimbursement information; financial administration of patient reimbursement programs, namely, copay financial assistance programs; financial administration of pharmacy reimbursement programs and services; providing patient support services, namely, providing insurance information to help patients understand their insurance and plan benefits, providing information on insurance authorization forms, appeals and status, providing information on insurance-approved site-of-care facilities, and providing insurance reimbursement assistance to eligible patients in the nature of reimbursement payment processing in the field of health and pharmaceutical insurance claims; patient support program, namely, providing information about eligibility for financial assistance provided through patient benefits programs; providing consulting in the field of healthcare insurance benefits; healthcare insurance services, namely, benefit verification services
10.
PHARMACEUTICAL COMPOSITION HAVING EXCELLENT DRUG ABSORPTION INTO THE LIVING BODY AND EXCELLENT CHEMICAL STABILITY
A medicinal composition containing a scopolamine salt and/or a hydrate thereof, polyvinylpyrrolidone, and a base. The medicinal composition is excellent in terms of absorption of the drug into the living body and chemical stability thereof.
A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A stent having a cylindrical shape when in a self-expanded state, wherein said stent is equipped with a first wire group comprising a plurality of wires and a second wire group comprising a plurality of wires intersecting the wires of the first wire group at a plurality of locations, the wires of the first wire group and the second wire group intersect and form a plurality of cells having a substantially rhomboid shape when in the cylindrical, self-expanded state, and the cross-sectional shape of each of the wires forms a thick rectangular shape in the radial direction of the cylindrical shape.
A61F 2/915 - Stents ayant une forme caractérisée par des éléments filiformesStents ayant une forme caractérisée par une structure de type filet ou de type à mailles caractérisés par une structure de type filet ou de type à mailles fabriquée à partir de feuilles perforées ou de tubes perforés, p. ex. perforés par découpe au laser ou gravés avec des bandes présentant une structure en méandre, des bandes adjacentes étant reliées l’une à l’autre
12.
PATCH FOR RELIEVING OR TREATING SYMPTOM OF NEURODEGENERATIVE DISEASE
The problem addressed by the present invention is to provide a novel patch for relieving or treating a symptom of a neurodegenerative disease. According to the present invention, provided is a patch for relieving or treating a symptom of a neurodegenerative disease, containing a salt of scopolamine and/or a hydrate thereof, said patch having an application duration per one time of 48 hours or less.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The present invention improves the stability of a medicine by suppressing oxygen degradation of a component which is blended in the medicine and is deteriorated by oxygen. A medicine set 1 according to the present invention is configured to comprise a PTP sheet in which medicines that contain a component that is deteriorated by oxygen are separately contained, a deoxygenating agent 4, and an outer package 2 which contains the deoxygenating agent 4 together with the PTP sheet, said outer package 2 being formed of a gas barrier material.
[Problem] To provide a medication assistance program and the like which assist taking medication. [Solution] To assist taking medication, a medication assistance program 10 causes a user terminal 20 to execute: a step of notifying a user that the time for medication is approaching; a step of displaying a medication confirmation screen that includes an affirmative button which is pressed when medication is taken, and a negative button which is pressed when medication could not be taken; a step of storing reward data in a storage unit of the user terminal when the affirmative button is pressed; and a step of displaying a screen showing the reward data.
A61J 7/04 - Dispositions pour l'indication ou le rappel du moment où l'on doit prendre des médicaments, p. ex. distributeurs programmés
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
[Problem] To provide granules having melatonin as an active ingredient. [Solution] A production method for melatonin-containing granules, said production method being characterized by including a granulation step for mixing melatonin and core particles having oral solubility in the presence of a binding agent to obtain melatonin granules, and a drying step for drying the melatonin granules obtained during the granulation step; and granules produced via said production method.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
[Problem] To provide an external preparation that contains rapamycin, has high stability and is efficacious in treating skin diseases. [Solution] An external preparation that contains (a) rapamycin, (b) at least one member selected from the group consisting of ethylene glycol salicylate, diethyl sebacate and triacetin, and (c) propylene glycol and/or polyethylene glycol, an external preparation that further contains an antioxidant, and an external preparation that further contains a solution of an antioxidant in a lipophilic solvent.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
[Problem] To provide granules for improving difficulty in sleep onset that target sleep disorders associated with neurodevelopmental disorders in infancy, ensure safety to young children, make it possible to obtain a sufficient effect, are used in a manner elaborated with due consideration to safety and effect, and are easy for infants and young children to swallow. [Solution] Granules for improving difficulty in sleep onset that contain melatonin as an active ingredient and that are produced by a method including: a granulation step in which orally soluble core particles and melatonin are mixed in the presence of a binder and melatonin base particles are obtained; and a drying step in which the melatonin base particles obtained in the granulation step are dried. The granules are characterized by targeting difficulty in sleep onset accompanying neurodevelopmental disorders in infancy, and in that a dose thereof equivalent to 1-4 mg of melatonin is administered orally once a day prior to bedtime.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
[Problem] To provide a technique of producing a gelatin sponge, capable of improving the healing rate of therapy of a perforated eardrum using a gelatin sponge carrying a basic fibroblast growth factor. [Solution] This production method for a gelatin sponge comprises (1) a step for foaming an aqueous gelatin solution, (2) a step for obtaining a xerogel by lyophilization of the aqueous gelatin solution foamed in step (1), and (3) a step for sterilizing the xerogel obtained in step (2), and is characterized in that the sterilization process in step (3) is performed by a radiation irradiation process. This gelatin sponge is produced by said method.
[Problem] To provide a granule in which the unpleasant taste of an active ingredient is masked and the rapid-release of the active ingredient is maintained, and a method for producing the same; and in particular, to provide a granule containing zinc acetate as an active ingredient having an unpleasant taste, and a method for producing the same. [Solution] This method for producing a granule, in which the unpleasant taste of an active ingredient is masked and the rapid-release of the active ingredient is maintained, comprises: (1) a step for obtaining core particles which contain an active ingredient having an unpleasant taste; (2) a step for coating the surfaces of the core particles obtained in step (1) with ethyl cellulose; and (3) a step for heating, in a sealed state, the particles obtained in step (2).
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A medicinal composition containing a scopolamine salt and/or a hydrate thereof, polyvinylpyrrolidone, and a base. The medicinal composition is excellent in terms of absorption of the drug into the living body and chemical stability thereof.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
23.
COMPOSITION FOR TREATING SENSORINEURAL HEARING LOSS
[Problem] To provide a composition for treating sensorineural hearing loss that is free from crosslinking agents and has an improved safety. [Solution] A composition for treating sensorineural hearing loss wherein a substance having an effect of protecting hair cells is carried on a porous carrier formed of a bioabsorbable polymer, and a kit therefor. In particular, a composition for treating sensorineural hearing loss wherein insulin-like growth factor 1 (IGF-1) is carried on a gelatin sponge, and a kit therefor.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations. Medical apparatus and instruments. Providing information via the Internet relating to pharmaceutical preparations and medical services; providing information relating to pharmaceutical preparations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations. Medical apparatus and instruments. Providing information via the Internet relating to pharmaceutical preparations and medical services; providing information relating to pharmaceutical preparations.
[Problem] To provide a therapeutic agent for acute herpes zoster pain. [Solution] A therapeutic agent for acute herpes zoster pain, which comprises as an active ingredient a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin) valeric acid and ethotoin, and a medicinal composition.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for skin care; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for the treatment of skin disorders associated with Tuberous sclerosis
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for skin care; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for the treatment of skin disorders associated with Tuberous sclerosis Scientific investigations for medical purposes; Scientific research; Medical research; Scientific research and development; Scientific laboratory services Medical clinic services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for skin care; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for the treatment of skin disorders associated with Tuberous sclerosis (Based on 44(e)) Scientific investigations for medical purposes; Scientific research; Medical research; Scientific research and development; Scientific laboratory services (Based on 44(e)) Medical clinic services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories
The purpose of the present invention is to provide a thyroid cartilage-shape measurement jig with which the shape of the front surface of thyroid cartilage can be easily measured. A thyroid cartilage-shape measurement jig (20) according to the present invention has: a plurality of movable members (21) which can slide relative to each other; a display unit (22) which displays the shape of thyroid cartilage (11) by bringing distal end surfaces (21t) of the movable members (21) into contact with the front surface (11a) of the thyroid cartilage (11); and a holding part (23) which can hold the movable members (21) such that the movable members (21) are arranged in one direction while fixing the movable members (21) that were slid. Also, two of the display units (22) can be provided spaced apart from each other in said one direction.
A61B 17/24 - Instruments, dispositifs ou procédés chirurgicaux pour la cavité buccale, le larynx, les conduits des bronches ou le nezGrattoirs pour la langue
A61B 5/107 - Mesure de dimensions corporelles, p. ex. la taille du corps entier ou de parties de celui-ci
A61F 2/20 - LarynxTrachées combinées avec larynx ou pour usage combiné
[Problem] To provide an ear treatment instrument for facilitating insertion of a scalpel or other instrument in the ear treatment instrument and in-ear medical treatment or surgery. [Solution] This ear treatment instrument 1 is provided with an insertion part 2 inserted in an ear canal, the insertion part 2 being cylindrically formed in a trumpet shape, and a support part 3 for supporting an instrument inserted in the insertion part 2 is provided to the inner circumferential surface 2a of the insertion part 2 or to a distal-end open end part thereof. The support part 3 may be formed by a projection protruding from the inner circumferential surface 2a of the insertion part 2, and the support part 3 may be formed on a distal-end side in the direction of an axis line L1 of the insertion part 2.
A61F 11/00 - Procédés ou dispositifs pour le traitement des oreilles ou de l'ouie Prothèses auditives non électriquesProcédés ou dispositifs permettant au patient d’obtenir une perception auditive par des sens physiologiques autres que l’ouïeDispositifs de protection pour les oreilles, portés sur le corps ou dans la main
A61B 1/227 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour les oreilles, c.-à-d. otoscopes
37.
Agent for regenerating tympanic membrane or external auditory canal
Provided is a tympanic membrane or ear canal regeneration agent comprising a combination of a gelatin sponge that carries basic fibroblast growth factor (bFGF) and a covering material. The covering material is used not only to fix the gelatin sponge to the affected portion, but also for the purpose of preventing drying and infections to provide a culturing environment that is favorable for regenerating tissue isolated from the outside. To promote tissue regeneration, the margin of the tympanic membrane or ear canal defect is preferably freshened in advance.
[Problem] To provide a molding jig for a dysphonia treatment tool with which a front piece can be bent at a position through which a hole does not pass. [Solution] A molding jig 20C for deforming a dysphonia treatment tool X having: a plurality of holding parts, each of which comprises a front piece 1a to be positioned on the front surface of incised thyroid cartilage and a rear piece to be positioned on the rear surface of the thyroid cartilage, the holding parts being fitted to the opposing incised end parts of the thyroid cartilage; and a bridging part for connecting the plurality of holding parts to each other. The dysphonia treatment tool X has holes formed in the front pieces thereof. The molding jig 20C comprises a clip part 22 having a pair of holding parts 21a, 21b for sandwiching the front pieces 1a from both surfaces and covering at least some of the holes 3.
A61B 17/24 - Instruments, dispositifs ou procédés chirurgicaux pour la cavité buccale, le larynx, les conduits des bronches ou le nezGrattoirs pour la langue
A61F 2/20 - LarynxTrachées combinées avec larynx ou pour usage combiné
42.
THERAPEUTIC AGENT USING ESTROGEN RECEPTOR β PARTIAL AGONIST HAVING ESTROGEN RECEPTOR α INHIBITING EFFECT, FOR PAIN AND/OR STRUCTURAL LESION FROM GYNECOLOGICAL DISORDER SUCH AS ENDOMETRIOSIS AND UTERUS ADENOMYOSIS
NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (Japon)
Inventeur(s)
Nakao Kenichiro
Harada Tasuku
Taniguchi Fuminori
Abrégé
[Problem] To provide a pharmaceutical agent for treatment of pain associated with a gynecological disorder and/or treatment of a structural lesion caused by a gynecological disorder. [Solution] A therapeutic agent for pain associated with a gynecological disorder and/or a structural lesion caused by the gynecological disorder, the therapeutic agent containing an estrogen receptor α inhibiting β partial agonist represented by structural formula (a), a pharmaceutically acceptable salt thereof, or a hydrate thereof as an effective component.
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
43.
Preparation jig for tympanic membrane regenerating agent and preparation vessel for tympanic membrane regenerating agent
[Problem] The present invention provides a preparation jig for a tympanic membrane regenerating agent and a preparation vessel for a tympanic membrane regenerating agent enabling simple preparation of a tympanic membrane regenerating agent.
h) side of the interior space (S1) is an installation space (S2) in which the holding portion (4A) is disposed.
A61F 11/00 - Procédés ou dispositifs pour le traitement des oreilles ou de l'ouie Prothèses auditives non électriquesProcédés ou dispositifs permettant au patient d’obtenir une perception auditive par des sens physiologiques autres que l’ouïeDispositifs de protection pour les oreilles, portés sur le corps ou dans la main
A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
[Problem] To provide a dysphonia treatment tool having front surface pieces that are bent. [Solution] The present invention is provided with: a plurality of clamping sections 1, 1 having a front surface piece 1a, which is to be positioned from an incision end face to the front surface of an incised thyroid cartilage, and a rear surface piece 1b, which is to be positioned on the rear surface of the thyroid cartilage, and being fitted to the mutually-facing incised ends of the thyroid cartilage; and a bridging section 2 connecting the plurality of clamping sections 1, 1. The front surface pieces 1a are bent in a middle section between the proximal end and distal end thereof.
A61B 17/24 - Instruments, dispositifs ou procédés chirurgicaux pour la cavité buccale, le larynx, les conduits des bronches ou le nezGrattoirs pour la langue
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 17/02 - Instruments, dispositifs ou procédés chirurgicaux pour maintenir les blessures ouvertes, p. ex. rétracteursÉcarteurs
[Problem] To provide a protein measurement method and the like having excellent sensitivity, trueness, and precision. [Solution] A protein measurement method comprising: an antigen binding step S16 in which a protein related to a genetic disease is made to bind with a capture antibody that recognizes said protein; a detection antibody binding step S17 in which said protein bound to said capture antibody is made to bind with a detection antibody that recognizes a region different from the region recognized by said capture antibody of said protein and that is labeled with a luminescent metal complex; and a measurement step S19 in which said detection antibody bound to said protein and labeled with said luminescent metal complex is detected by measuring the electrochemiluminescence generated by electrochemical stimulation.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
[Problem] The present invention provides a preparation jig for a tympanic membrane regenerating agent and a preparation vessel for a tympanic membrane regenerating agent that can easily prepare a tympanic membrane regenerating agent. [Solution] This preparation jig for a tympanic membrane regenerating agent 1a and preparation vessel for a tympanic membrane regenerating agent 1A are equipped with: a vessel 3A provided with housing walls 6, 7 that form an interior space S1 in which a medicinal solution support 2 is housed, and that have an opening 6h formed therein that opens in one direction; and a holding part 4A that is disposed in the interior space S1. The deep side of the interior space S1 is a housing portion S3 for accommodating the medicinal solution support 2, which holds a medicinal solution. The opening 6h side of the interior space S1 is an installation space S2 in which the holding part 4A is disposed.
A61F 11/00 - Procédés ou dispositifs pour le traitement des oreilles ou de l'ouie Prothèses auditives non électriquesProcédés ou dispositifs permettant au patient d’obtenir une perception auditive par des sens physiologiques autres que l’ouïeDispositifs de protection pour les oreilles, portés sur le corps ou dans la main
48.
VOICE DISORDER TREATMENT TOOL AND VOICE DISORDER TREATMENT SET
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
WAKAYOSHI SEISAKUSHO CO., LTD. (Japon)
Inventeur(s)
Sanuki Tetsuji
Wakayoshi Shuji
Harada Tsukasa
Masuda Seiichi
Nishihata Hiroyuki
Kinoshita Kazuhiro
Aburada Takako
Abrégé
Provided is a voice disorder treatment tool in which a clamping section thereof does not break easily, and which is characterized by being equipped with: a plurality of clamping sections (1, 1) that each have a front surface piece (1b) disposed on the front surface of cut thyroid cartilage and a rear surface piece (1c) disposed on the rear surface of the thyroid cartilage, and are formed so as to fit to each of the mutually facing incision ends of the cut thyroid cartilage; and a bridging section (2) connecting the plurality of clamping sections (1, 1). Each front surface piece (1b) has a bending region (15) that allows the front surface piece (1b) to deform about a virtual line extending in the width direction, and the bending region (15) has a reinforcing structure (S).
A61B 17/24 - Instruments, dispositifs ou procédés chirurgicaux pour la cavité buccale, le larynx, les conduits des bronches ou le nezGrattoirs pour la langue
A61F 2/20 - LarynxTrachées combinées avec larynx ou pour usage combiné
49.
ESTROGEN RECEPTOR β PARTIAL AGONIST HAVING ESTROGEN RECEPTOR α INHIBITORY EFFECT, AND THERAPEUTIC AGENT FOR GYNECOLOGICAL DISORDERS USING SAME
NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (Japon)
Inventeur(s)
Nakao Kenichiro
Harada Tasuku
Taniguchi Fuminori
Abrégé
[Problem] To provide a therapeutic agent for estrogen-dependent gynecological disorders such as endometriosis, uterine fibroids, and adenomyosis. [Solution] An estrogen receptor α-inhibiting β partial agonist represented by structural formula (a), a pharmaceutically-acceptable salt thereof, or a hydrate of either of the aforementioned is used as an active ingredient.
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
50.
Maleic acid salt of anti-prion compound, method for producing the same and pharmaceutical composition of the same
An object of the present invention is to provide an anti-prion compound that has high crystallinity and is highly stable in the crystalline form and to provide a medicament for preventing, ameliorating or treating a prion disease. The present invention provides a maleic acid salt of a compound represented by formula (1):
C07D 295/15 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec les atomes d'azote du cycle et les atomes de carbone comportant trois liaisons à des hétéro-atomes liés à la même chaîne carbonée, qui n'est pas interrompue par des carbocycles à une chaîne acyclique saturée
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for treating tympanic membrane perforation or ear canal soft tissue defect; pharmaceutical preparations for treating skin disorders; vaccines; vaccines for treating malaria. Medical apparatus and instruments; medical apparatus and instruments for treating spasmodic dysphonia; medical apparatus and instruments for type 2 thyroplasty. Providing medical information; providing pharmaceutical information; medical and pharmaceutical consultation.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations for treating tympanic membrane perforation and ear canal soft tissue defect; pharmaceutical preparations for treating skin disorders; vaccines; vaccines for treating malaria [ Medical apparatus and instruments for treating spasmodic dysphonia; medical apparatus and instruments for type 2 thyroplasty ] Providing medical information; providing pharmaceutical information; medical and pharmaceutical consultation
53.
TABLET COMPRISING ZINC ACETATE HYDRATE AND METHOD FOR MANUFACTURING SAME
Provided are: a compact-sized granulate of zinc acetate hydrate, in which the loss of crystallization water is suppressed during a manufacturing process by controlling the material temperature of the granulate to lower than 40°C during the manufacturing process and which has a small occupied volume; and a method for manufacturing the same. The granulate is in the form of a tablet comprising zinc acetate hydrate, said tablet containing 5-200 mg of zinc acetate hydrate (C4H6O4Zn·2H2O), having a diameter of 5-12 mm and a thickness of 1-6 mm, and showing an elution ratio of zinc of 85% or more after 15 minutes when measured in accordance with the Japanese pharmacopeia elution method (paddle method: 50 rpm, test liquid: water 900 ml).
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Provided is a tympanic membrane or ear canal regeneration agent comprising a combination of a gelatin sponge that carries basic fibroblast growth factor (bFGF) and a covering material. The covering material is used not only to fix the gelatin sponge to the affected portion, but also for the purpose of preventing drying and infections to provide a culturing environment that is favorable for regenerating tissue isolated from the outside. To promote tissue regeneration, the margin of the tympanic membrane or ear canal defect is preferably freshened in advance.
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
NOBELPHARMA CO., LTD. (Japon)
Inventeur(s)
Sanuki Tetsuji
Abrégé
A titanium spacer for accurately and quickly determining the size of a bridge inserted to dilate and fix a thyroid cartilage incision in a patient in type II thyroplasty, wherein the titanium spacer is provided with a knob part, a body part continuing from the knob part, two large wing parts extending from the body part in a laterally symmetrical shape perpendicular to the knob part, and two small wing parts extending laterally from the body part so as to be parallel to the large wing parts, the small wing parts constituting the bottom surface of the titanium spacer together with the bottom surface of the body part. The large wing parts, the body part continuing from the large wing parts, and the small wing parts continuing from the body part constitute a size-determining part for determining the size of a clamping part of the bridge. In addition, a kit.
A61B 17/24 - Instruments, dispositifs ou procédés chirurgicaux pour la cavité buccale, le larynx, les conduits des bronches ou le nezGrattoirs pour la langue
A61B 17/02 - Instruments, dispositifs ou procédés chirurgicaux pour maintenir les blessures ouvertes, p. ex. rétracteursÉcarteurs
[Problem] The problem of the present invention is to provide a novel pyruvate dehydrogenase inhibitor. [Solution] Provided are a pyruvate dehydrogenase inhibitor comprising the compound represented by general formula (I) as the active ingredient (where in the formula, ring A is a six-member hydrocarbon ring having aromaticity that is optionally substituted by two to four substitution groups, R1 and R4 are the same or different and are, for instance, a hydrogen atom, hydroxyl group, or optionally substituted C1-6 alkyl group, and R2 and R3 are the same or different and are a hydrogen atom, carboxyl group, optionally substituted C1-6 alkyl group, C6-10 aryl group, or -C(=R9)-R10); a medical composition which comprises the pyruvate dehydrogenase kinase inhibitor as the active ingredient and which is for treating or preventing a disease or an impairment the development or deterioration of which is associated with pyruvate dehydrogenase kinase; and a cosmetic composition, and the like.
Provided is a tympanic membrane or ear canal regeneration agent comprising a combination of a gelatin sponge that carries basic fibroblast growth factor (bFGF) and a covering material. The covering material is used not only to fix the gelatin sponge to the affected portion, but also for the purpose of preventing drying and infections to provide a culturing environment that is favorable for regenerating tissue isolated from the outside. To promote tissue regeneration, the margin of the tympanic membrane or ear canal defect is preferably freshened in advance.
A medicinal composition containing a scopolamine salt and/or a hydrate thereof, polyvinylpyrrolidone, and a base. The medicinal composition is excellent in terms of absorption of the drug into the living body and chemical stability thereof.
A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
[Problem] To provide an external preparation that contains rapamycin, has high stability and is efficacious in treating skin diseases. [Solution] An external preparation that contains (a) rapamycin, (b) at least one member selected from the group consisting of ethylene glycol salicylate, diethyl sebacate and triacetin, and (c) propylene glycol and/or polyethylene glycol, an external preparation that further contains an antioxidant, and an external preparation that further contains a solution of an antioxidant in a lipophilic solvent.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
60.
AGENT FOR REGENERATING TYMPANIC MEMBRANE OR EXTERNAL AUDITORY CANAL
Provided is a tympanic membrane or ear canal regeneration agent comprising a combination of a gelatin sponge that carries basic fibroblast growth factor (bFGF) and a covering material. The covering material is used not only to fix the gelatin sponge to the affected portion, but also for the purpose of preventing drying and infections to provide a culturing environment that is favorable for regenerating tissue isolated from the outside. To promote tissue regeneration, the margin of the tympanic membrane or ear canal defect is preferably freshened in advance.
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
NOBELPHARMA CO., LTD. (Japon)
WAKAYOSHI SEISAKUSHO CO., LTD. (Japon)
Inventeur(s)
Sanuki, Tetsuji
Wakayoshi, Shuji
Harada, Tsukasa
Masuda, Seiichi
Nishihata, Hiroyuki
Kinoshita, Kazuhiro
Aburada, Takako
Abrégé
Provided is a voice disorder treatment tool in which a clamping section thereof does not break easily, and which is characterized by being equipped with: a plurality of clamping sections (1, 1) that each have a front surface piece (1b) disposed on the front surface of cut thyroid cartilage and a rear surface piece (1c) disposed on the rear surface of the thyroid cartilage, and are formed so as to fit to each of the mutually facing incision ends of the cut thyroid cartilage; and a bridging section (2) connecting the plurality of clamping sections (1, 1). Each front surface piece (1b) has a bending region (15) that allows the front surface piece (1b) to deform about a virtual line extending in the width direction, and the bending region (15) has a reinforcing structure (S).
A61B 17/24 - Instruments, dispositifs ou procédés chirurgicaux pour la cavité buccale, le larynx, les conduits des bronches ou le nezGrattoirs pour la langue
A61F 2/20 - LarynxTrachées combinées avec larynx ou pour usage combiné
62.
GRANULE HAVING MASKED UNPLEASANT TASTE AND METHOD FOR PRODUCING SAME
[Problem] To provide a granule in which the unpleasant taste of an active ingredient is masked and the rapid-release of the active ingredient is maintained, and a method for producing the same; and in particular, to provide a granule containing zinc acetate as an active ingredient having an unpleasant taste, and a method for producing the same. [Solution] This method for producing a granule, in which the unpleasant taste of an active ingredient is masked and the rapid-release of the active ingredient is maintained, comprises: (1) a step for obtaining core particles which contain an active ingredient having an unpleasant taste; (2) a step for coating the surfaces of the core particles obtained in step (1) with ethyl cellulose; and (3) a step for heating, in a sealed state, the particles obtained in step (2).
The problem addressed by the present invention is to provide a novel patch for relieving or treating a symptom of a neurodegenerative disease. According to the present invention, provided is a patch for relieving or treating a symptom of a neurodegenerative disease, containing a salt of scopolamine and/or a hydrate thereof, said patch having an application duration per one time of 48 hours or less.
A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
